High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting

NAVIGATORE-Lombardia Study Group, M. Fabbiani, A. Lombardi, M. Colaneri, P. Del Poggio, P. Perini, R. D'Ambrosio, E. Degasperi, C. Dibenedetto, A. Giorgini, L. Pasulo, F. Maggiolo, F. Castelli, P. Brambilla, O. Spinelli, T. Re, A. Lleo, M. Rumi, C. Uberti-Foppa, A. SoriaA. Aghemo, P. Lampertico, C. Baiguera, M. Schiavini, S. Fagiuoli, R. Bruno

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)558-568
Number of pages11
JournalJournal of Viral Hepatitis
Issue number3
Publication statusPublished - 2021


  • antivirus agent
  • daclatasvir
  • dasabuvir plus ombitasvir plus paritaprevir plus ritonavir
  • elbasvir plus grazoprevir
  • glecaprevir plus pibrentasvir
  • ledipasvir plus sofosbuvir
  • ombitasvir plus paritaprevir plus ritonavir
  • simeprevir
  • sofosbuvir
  • sofosbuvir plus daclatasvir
  • sofosbuvir plus simeprevir
  • sofosbuvir plus velpatasvir
  • unclassified drug
  • adult
  • aged
  • antiviral therapy
  • Article
  • chronic hepatitis C
  • cohort analysis
  • coinfection
  • controlled study
  • female
  • genotype
  • Hepatitis C virus genotype 2
  • Hepatitis C virus genotype 3
  • Hepatitis C virus genotype 4
  • Hepatitis C virus subtype 1a
  • Hepatitis C virus subtype 1b
  • human
  • Human immunodeficiency virus infection
  • liver cirrhosis
  • major clinical study
  • male
  • prospective study
  • retrospective study
  • study design
  • sustained virologic response
  • treatment duration

Cite this